Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction | Zendy

Thomas A. Gaziano | Zendy; Gregg C. Fonarow | Zendy; Eric J. Velazquez | Zendy; David A. Morrow | Zendy; Eugene Braunwald | Zendy; Scott D. Solomon | Zendy

Open Access

Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction

Author(s) -

Thomas A. Gaziano,

Gregg C. Fonarow,

Eric J. Velazquez,

David A. Morrow,

Eugene Braunwald,

Scott D. Solomon

Publication year - 2020

Publication title -

jama cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.108

H-Index - 63

eISSN - 2380-6591

pISSN - 2380-6583

DOI - 10.1001/jamacardio.2020.2822

Subject(s) - sacubitril, valsartan , enalapril , medicine , sacubitril , valsartan , ejection fraction , heart failure , cardiology , angiotensin converting enzyme , blood pressure

Sacubitril-valsartan use reduces mortality and hospitalizations compared with enalapril among patients with chronic heart failure with reduced ejection fraction (HFrEF); however, the cost-effectiveness of these treatments when initiated during hospitalization for HF is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research